via University of Turku
A research group at the University of Turku has led the development of a new method to evaluate vaccine safety. The new method may significantly reduce the use of animal testing in the vaccine industry.
Vaccines are safe and potent pharmaceutical products that prevent infectious diseases caused by viruses and bacteria, and reduce the spread of pathogens among the population. A vaccine prevents an infectious disease because the body develops an ability to recognise and destroy the pathogen. Vaccines are generally designed from a weakened pathogen, or parts of it. The vaccine industry uses effective methods to ensure vaccine safety, and constantly develops new methods as well.
The pertussis vaccine, which also belongs to the Finnish national vaccination programme, contains the surface structures of the pertussis bacteria and inactivated forms of the pertussis toxin produced by the bacteria. The pertussis toxin attaches to the surface of the cell, penetrates it, and destroys the vital control system of the cell.
The research group at the University of Turku has led the development of the new method that can be used to ensure the safety of the pertussis toxin in the pertussis vaccine. The new iGIST method (Interference in G?i-mediated Signal Transduction) detects how the pertussis toxin destroys the vital control system of the cell.
– Compared to the current methods in the vaccine industry, iGIST is more effective and enables the detection of up to 100 times lower levels of pertussis toxin. iGIST is entirely based on using laboratory grown, human-based cells. Therefore, it may significantly reduce the use of animal testing in the vaccine industry, says Dr Arto Pulliainen from the University of Turku who was the principal investigator of the research group that was in charge of developing the method.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Safety the priority in vaccinating children
The risks of vaccination for children must be balanced against the risk of disease, and when it comes to Covid-19, caution is warranted, argues Tony Walls.
- Doubts on safety, efficacy in children underlie parents' vaccine hesitancy: POLL
Half of parents in a new ABC News/Washington Post poll are skeptical about the safety and effectiveness of COVID-19 vaccines for children, potentially a key barrier as the ...
- How did we develop a COVID-19 vaccine so quickly?
In this Special Feature, we speak with medical experts about how scientists made coronavirus vaccines so rapidly without compromising safety. Share on Pinterest Image credit: VICTORIA JONES/Getty ...
- PA Officials Address Vaccine Safety For Children [Watch Live]
Join some of Pennsylvania's top medical minds Friday afternoon as they address the safety of the vaccine for children ages 5 to 11.
- The COVID-19 vaccine and kids. Your questions answered
Through this smartphone app, people who have been vaccinated can report how they are feeling after receiving their dose, to help researchers who are collecting and analyzing vaccine safety ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Vaccine safety evaluation
- Efficacy and safety of an RBD-based recombinant protein COVID-19 vaccine
Study: Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2. Image Credit: Tero ...
- 'Complex’ new coronavirus variant ‘could well defeat the vaccine’, warns UK minister
The government has said it is urgently investigating the new coronavirus variant amid warnings it "could defeat the vaccine". The UK is one of a number of countries to respond to the emergence of the ...
- Clover’s COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
(“Clover”; Stock code: 2197.HK), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that an investigator-led, Phase 2 trial ...
- Benefits Outweigh Risks of Pediatric COVID-19 Vaccine, Contrary to Posts Misusing VAERS Data
Viral social media posts continue to misuse the Vaccine Adverse Event Reporting System data, and flawed calculations, to claim the Pfizer COVID-19 vaccine for children is unsafe and will cause many ...
- Novavax applies to Singapore's HSA for approval to use its COVID vaccine
American biotechnology company Novavax said it has filed for interim authorisation with Singapore's Health Sciences Authority for use of its COVID-19 vaccine under the pandemic special access route.